DaVita Stock Forecast, Price & News

DaVita's stock was trading at $74.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, DVA stock has increased by 47.2% and is now trading at $110.24.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DaVita in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for DaVita.

Wall Street analysts have given DaVita a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DaVita wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

DaVita is scheduled to release its next quarterly earnings announcement on Monday, February 8th 2021.
View our earnings forecast for DaVita.

DaVita Inc. (NYSE:DVA) issued its quarterly earnings data on Thursday, October, 29th. The company reported $1.80 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.44 by $0.36. The business earned $2.92 billion during the quarter, compared to analysts' expectations of $2.94 billion. DaVita had a net margin of 7.32% and a return on equity of 43.99%. DaVita's quarterly revenue was up .7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.53 EPS.
View DaVita's earnings history.

DaVita issued an update on its fourth quarter earnings guidance on Thursday, October, 29th. The company provided earnings per share (EPS) guidance of $1.77-2.02 for the period, compared to the Thomson Reuters consensus estimate of $1.67. The company issued revenue guidance of $2.85-2.96 billion, compared to the consensus revenue estimate of $2.94 billion.

6 brokerages have issued 1 year price targets for DaVita's shares. Their forecasts range from $60.00 to $100.00. On average, they anticipate DaVita's share price to reach $77.50 in the next twelve months. This suggests that the stock has a possible downside of 29.7%.
View analysts' price targets for DaVita.

DaVita saw a increase in short interest in October. As of October 15th, there was short interest totaling 5,610,000 shares, an increase of 16.1% from the September 30th total of 4,830,000 shares. Based on an average daily trading volume, of 1,090,000 shares, the days-to-cover ratio is currently 5.1 days. Currently, 4.7% of the company's shares are sold short.
View DaVita's Short Interest.

Some companies that are related to DaVita include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Amedisys (AMED), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), The Providence Service (PRSC), MEDNAX (MD), CorVel (CRVL), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Biosciences (IDXG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DaVita investors own include CA (CA), BlackRock (BLK), Chipotle Mexican Grill (CMG), Endologix (ELGX), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), AT&T (T), AbbVie (ABBV), Intel (INTC) and AutoZone (AZO).

DaVita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."

DaVita's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.69%), State Street Corp (3.53%), LSV Asset Management (2.00%), Robeco Institutional Asset Management B.V. (1.42%), Charles Schwab Investment Management Inc. (0.55%) and UBS Asset Management Americas Inc. (0.53%). Company insiders that own DaVita stock include Barbara J Desoer, Charles Berg, John M Nehra, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway, Paul J Diaz and R Ted Weschler.
View institutional ownership trends for DaVita.

DVA stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, BlackRock Inc., State Street Corp, Mackay Shields LLC, Wedge Capital Management L L P NC, Achmea Investment Management B.V., Los Angeles Capital Management & Equity Research Inc., and Great West Life Assurance Co. Can. Company insiders that have sold DaVita company stock in the last year include Barbara J Desoer, Charles Berg, John M Nehra, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway, Paul J Diaz, and R Ted Weschler.
View insider buying and selling activity for DaVita.

DVA stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, Jupiter Asset Management Ltd., Iron Triangle Partners LP, AJO LP, First Trust Advisors LP, Point72 Asset Management L.P., Todd Asset Management LLC, and Sei Investments Co..
View insider buying and selling activity for DaVita.

Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DVA stock can currently be purchased for approximately $110.24.

DaVita has a market capitalization of $12.35 billion and generates $11.39 billion in revenue each year. The company earns $810.98 million in net income (profit) each year or $5.40 on an earnings per share basis. DaVita employs 65,000 workers across the globe.

The official website for DaVita is www.davita.com.

DaVita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 720-631-2100 or via email at [email protected]